Neopharmed Gentili Acquires European Orladeyo Business from BioCryst

Neopharmed Gentili, an Italian pharmaceutical company co-owned by the Del Bono family and private equity firms Ardian and Renaissance Partners, has agreed to acquire the European business of Orladeyo (berotralstat) from BioCryst Pharmaceuticals for an initial payment of $250 million. Orladeyo is an oral treatment for hereditary angioedema (HAE). The acquisition is part of Neopharmed’s strategy to replicate its Italian success across Europe, expanding into the rare diseases sector characterized by high value and rapid growth. PwC advised Neopharmed on financial and tax aspects, while Centerview Partners, White & Case, ZS Associates, and ValueVector provided various consultancy services. For BioCryst, BofA Securities, TD Securities, and Skadden, Arps, Slate, Meagher & Flom served as advisors. The transaction, set to close in October 2025 pending customary conditions, also involves potential milestone payments tied to sales in Central and Eastern Europe and will be financed through available liquidity and shareholder contributions. Neopharmed aims to leverage Orladeyo's platform and experienced team to position itself as a leading partner for rare disease assets in Europe, aligning with its long-term growth and portfolio expansion strategy.